BRAFi, which has been approved to treat advanced melanoma and proved to show strong clinical benefit in BRAFv600 melanoma [48, 176, 177], can also induce TXNIP expression through regulating the association between MondoA and TXNIP promoter [176]. Here, TXNIP is linked to melanoma.